t
| Date | 23 May 2022 |
| Time | 14:19:57 |
| Category | AGMs and other meetings |
| ID | 4721M |
Arecor Therapeutics plc
("Arecor" or the "Group")
RESULT OF AGM
Cambridge, UK, 23 May 2022: Arecor Therapeutics plc (AIM: AREC), the biopharmaceutical group advancing today's therapies to enable healthier lives, announces that at its Annual General Meeting, held today at 1.00 pm, all resolutions were duly passed.
-ENDS-
For more information, please contact:
|
Arecor Therapeutics plc |
|
|
Dr Sarah Howell, Chief Executive Officer |
Tel: +44 (0) 1223 426060 Email: [email protected] |
|
|
|
|
Susan Lowther, Chief Financial Officer |
Tel: +44 (0) 1223 426060 Email: [email protected] |
|
|
|
|
Mo Noonan, Communications |
Tel: +44 (0) 7876 444977 Email: [email protected] |
|
|
|
|
Panmure Gordon (UK) Limited (NOMAD and Broker) Freddy Crossley, Emma Earl (Corporate Finance) Rupert Dearden (Corporate Broking) |
Tel: +44 (0) 20 7886 2500
|
|
|
|
|
Consilium Strategic Communications |
|
|
Chris Gardner, David Daley, Angela Gray |
Tel: +44 (0) 20 3709 5700 Email: [email protected] |
Notes to Editors
About Arecor
Arecor Therapeutics plc is a globally focused biopharmaceutical company transforming patient care by bringing innovative medicines to market through the enhancement of existing therapeutic products. By applying our innovative proprietary formulation technology platform, Arestat™, we are developing an internal portfolio of proprietary products in diabetes and other indications, as well as working with leading pharmaceutical and biotechnology companies to deliver enhanced formulations of their therapeutic products. The Arestat™ platform is supported by an extensive patent portfolio.
For further details please see our website, www.arecor.com